<DOC>
	<DOCNO>NCT01392326</DOCNO>
	<brief_summary>This study ass efficacy safety secukinumab patient active psoriatic arthritis intolerant inadequate response NSAIDs , DMARDs / TNFα inhibitor therapy .</brief_summary>
	<brief_title>Efficacy 24 Weeks Long Term Safety , Tolerability Efficacy 2 Years Secukinumab ( AIN457 ) Patients With Active Psoriatic Arthritis ( PsA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Male nonpregnant , nonlactating female patient least 18 year age Diagnosis PsA classify CASPAR criterion symptoms least 6 month moderate severe PsA must Baseline ≥3 tender joint 78 ≥3 swell 76 ( dactylitis digit count one joint ) Rheumatoid factor antiCCP antibody negative Diagnosis active plaque psoriasis , least one psoriatic plaque ≥2cm diameter nail change consistent psoriasis document history plaque psoriasis Exclusion criterion : Chest Xray evidence ongoing infectious malignant process Subjects previously treat 3 different TNFα inhibitor Subjects take high potency opioid analgesic Subjects ever receive biologic immunomodulating agent except target TNFα Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Psoriatic arthritis</keyword>
	<keyword>PsA</keyword>
	<keyword>ACR</keyword>
	<keyword>CASPAR</keyword>
</DOC>